Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Baxter
Dow
McKinsey
Merck

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

US Patent Family Members and Approved Drugs for Australia Patent: 2003256335

See Plans and Pricing

« Back to Dashboard

US Patent Family Members and Approved Drugs for Australia Patent: AU2003256335

These international patent data are derived from patent families, based on US drug-patent linkages. Accordingly, they should not be regarded as comprehensive records of ex-US drug-patent associations.
US Patent Number Estimated Patent Expiration Generic Name US Applicant US Tradename
  Start Trial 2022-07-01 interferon alfa-2b Schering INTRON A
>US Patent Number >Estimated Patent Expiration >Generic Name >US Applicant >US Tradename

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Merck
Mallinckrodt
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.